CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on CervoMed, with a price target of $27.00.

Sumant Kulkarni has given his Buy rating due to a combination of factors related to CervoMed’s lead asset, neflamapimod, and the company’s valuation. He highlights that CervoMed has aligned with the FDA on the Phase 3 design in dementia with Lewy bodies, including dose and formulation, and sees multiple upcoming Phase 2a readouts in primary progressive aphasia and post-stroke recovery, as well as an ALS study start, as important value inflection points.

At the same time, he acknowledges that the company’s ability to fully exploit neflamapimod’s potential is constrained by a cash runway of less than a year and the need for substantial additional funding. Despite this financing overhang, he believes the scientific rationale behind neflamapimod in dementia with Lewy bodies is compelling, and his model still supports a discounted cash flow–based price target of $27, which implies the shares are significantly undervalued and justifies maintaining a Buy recommendation.

In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.